Neuropsychologic changes from before transplantation to 1 year in patients receiving myeloablative allogeneic hematopoietic cell transplant

Karen L. Syrjala, Sureyya Dikmen, Shelby Langer, Sari Roth-Roemer, Janet R. Abrams

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Research indicates that myeloablative hematopoietic cell transplantation (HCT) impairs neurocognitive function. However, prospective studies on long-term effects are lacking. This longitudinal study examined neurocognitive changes over the first year in 142 adult recipients of allogeneic HC transplants who received neuropsychologic testing before transplantation and again after 80 days and 1 year. Age-, sex-, and education-adjusted population-based standardized scores were used for normative comparisons. Performance on all tests declined from before transplantation to 80 days (P < .05) and improved by 1 year (P < .05), returning to pretransplantation levels on all tests except for grip strength and motor dexterity. Although verbal fluency and memory recovered by 1 year, both were below norms at all 3 testing times (P < .01). Logistic regressions indicated that patients without chemotherapy, other than hydroxyurea, previous to HCT and patients not receiving chronic graft-versus-host disease (GVHD) medication at 1 year had lower risk of impaired function (P < .05). In conclusion, HCT was associated with significant generalized decline in neurocognitive performance at 80 days, with subsequent recovery to pretransplantation levels by 1 year for most survivors, except on motor tasks. Results indicate that long-term cognitive decrements, as distinct from motor disabilities, infrequently derive directly from HCT.

Original languageEnglish (US)
Pages (from-to)3386-3392
Number of pages7
JournalBlood
Volume104
Issue number10
DOIs
StatePublished - Nov 15 2004
Externally publishedYes

Fingerprint

Transplantation (surgical)
Transplants
Cell Transplantation
Transplantation
Chemotherapy
Hydroxyurea
Testing
Grafts
Sex Education
Logistics
Hand Strength
Graft vs Host Disease
Education
Longitudinal Studies
Survivors
Data storage equipment
Recovery
Logistic Models
Prospective Studies
Drug Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Neuropsychologic changes from before transplantation to 1 year in patients receiving myeloablative allogeneic hematopoietic cell transplant. / Syrjala, Karen L.; Dikmen, Sureyya; Langer, Shelby; Roth-Roemer, Sari; Abrams, Janet R.

In: Blood, Vol. 104, No. 10, 15.11.2004, p. 3386-3392.

Research output: Contribution to journalArticle

Syrjala, Karen L. ; Dikmen, Sureyya ; Langer, Shelby ; Roth-Roemer, Sari ; Abrams, Janet R. / Neuropsychologic changes from before transplantation to 1 year in patients receiving myeloablative allogeneic hematopoietic cell transplant. In: Blood. 2004 ; Vol. 104, No. 10. pp. 3386-3392.
@article{1ab7c49e045642ebbcf67116e2f29dfa,
title = "Neuropsychologic changes from before transplantation to 1 year in patients receiving myeloablative allogeneic hematopoietic cell transplant",
abstract = "Research indicates that myeloablative hematopoietic cell transplantation (HCT) impairs neurocognitive function. However, prospective studies on long-term effects are lacking. This longitudinal study examined neurocognitive changes over the first year in 142 adult recipients of allogeneic HC transplants who received neuropsychologic testing before transplantation and again after 80 days and 1 year. Age-, sex-, and education-adjusted population-based standardized scores were used for normative comparisons. Performance on all tests declined from before transplantation to 80 days (P < .05) and improved by 1 year (P < .05), returning to pretransplantation levels on all tests except for grip strength and motor dexterity. Although verbal fluency and memory recovered by 1 year, both were below norms at all 3 testing times (P < .01). Logistic regressions indicated that patients without chemotherapy, other than hydroxyurea, previous to HCT and patients not receiving chronic graft-versus-host disease (GVHD) medication at 1 year had lower risk of impaired function (P < .05). In conclusion, HCT was associated with significant generalized decline in neurocognitive performance at 80 days, with subsequent recovery to pretransplantation levels by 1 year for most survivors, except on motor tasks. Results indicate that long-term cognitive decrements, as distinct from motor disabilities, infrequently derive directly from HCT.",
author = "Syrjala, {Karen L.} and Sureyya Dikmen and Shelby Langer and Sari Roth-Roemer and Abrams, {Janet R.}",
year = "2004",
month = "11",
day = "15",
doi = "10.1182/blood-2004-03-1155",
language = "English (US)",
volume = "104",
pages = "3386--3392",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Neuropsychologic changes from before transplantation to 1 year in patients receiving myeloablative allogeneic hematopoietic cell transplant

AU - Syrjala, Karen L.

AU - Dikmen, Sureyya

AU - Langer, Shelby

AU - Roth-Roemer, Sari

AU - Abrams, Janet R.

PY - 2004/11/15

Y1 - 2004/11/15

N2 - Research indicates that myeloablative hematopoietic cell transplantation (HCT) impairs neurocognitive function. However, prospective studies on long-term effects are lacking. This longitudinal study examined neurocognitive changes over the first year in 142 adult recipients of allogeneic HC transplants who received neuropsychologic testing before transplantation and again after 80 days and 1 year. Age-, sex-, and education-adjusted population-based standardized scores were used for normative comparisons. Performance on all tests declined from before transplantation to 80 days (P < .05) and improved by 1 year (P < .05), returning to pretransplantation levels on all tests except for grip strength and motor dexterity. Although verbal fluency and memory recovered by 1 year, both were below norms at all 3 testing times (P < .01). Logistic regressions indicated that patients without chemotherapy, other than hydroxyurea, previous to HCT and patients not receiving chronic graft-versus-host disease (GVHD) medication at 1 year had lower risk of impaired function (P < .05). In conclusion, HCT was associated with significant generalized decline in neurocognitive performance at 80 days, with subsequent recovery to pretransplantation levels by 1 year for most survivors, except on motor tasks. Results indicate that long-term cognitive decrements, as distinct from motor disabilities, infrequently derive directly from HCT.

AB - Research indicates that myeloablative hematopoietic cell transplantation (HCT) impairs neurocognitive function. However, prospective studies on long-term effects are lacking. This longitudinal study examined neurocognitive changes over the first year in 142 adult recipients of allogeneic HC transplants who received neuropsychologic testing before transplantation and again after 80 days and 1 year. Age-, sex-, and education-adjusted population-based standardized scores were used for normative comparisons. Performance on all tests declined from before transplantation to 80 days (P < .05) and improved by 1 year (P < .05), returning to pretransplantation levels on all tests except for grip strength and motor dexterity. Although verbal fluency and memory recovered by 1 year, both were below norms at all 3 testing times (P < .01). Logistic regressions indicated that patients without chemotherapy, other than hydroxyurea, previous to HCT and patients not receiving chronic graft-versus-host disease (GVHD) medication at 1 year had lower risk of impaired function (P < .05). In conclusion, HCT was associated with significant generalized decline in neurocognitive performance at 80 days, with subsequent recovery to pretransplantation levels by 1 year for most survivors, except on motor tasks. Results indicate that long-term cognitive decrements, as distinct from motor disabilities, infrequently derive directly from HCT.

UR - http://www.scopus.com/inward/record.url?scp=8644225828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8644225828&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-03-1155

DO - 10.1182/blood-2004-03-1155

M3 - Article

VL - 104

SP - 3386

EP - 3392

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -